Mycenax Biotech Inc. (TPEX:4726)

Market Cap	6.55B
Revenue (ttm)	649.64M
Net Income (ttm)	-479.46M
Shares Out	207.20M
EPS (ttm)	-2.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	224,106
Average Volume	208,046
Open	33.00
Previous Close	32.00
Day's Range	31.55 - 33.00
52-Week Range	27.40 - 46.00
Beta	0.51
RSI	47.38
Earnings Date	Feb 26, 2026

About Mycenax Biotech

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug conjugates, cell and gene therapy, and exosomes products and services. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 387
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4726

Financial Performance

In 2024, Mycenax Biotech's revenue was 683.92 million, an increase of 4.80% compared to the previous year's 652.62 million. Losses were -467.13 million, -31.59% less than in 2023.